We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced it has formed an agreement with the Texas Department of State Health Services (DSHS) to provide COVID-19...
A new Quest Diagnostics Health Trends® report developed in collaboration with the Centers for Disease Control and Prevention (CDC) found that the COVID-19 pandemic reduced routine hepatitis C virus (HCV) testing and treatment.
Quest Diagnostics has introduced a new COVID-19 testing service that aids in providing insight into an individual's immune response as a result of a recent or prior infection with SARS-CoV-2, the virus that causes COVID-19, or to immune response ...
Quest Diagnostics has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Quest Diagnostics Self-Collection Kit for COVID-19.
Quest Diagnostics is the first national laboratory provider in the United States to enable accurate nonfasting lipid testing using the novel method in patient testing